Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H17N3O |
| Molecular Weight | 207.2722 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(NCC1=CC=C(OC)C=C1)=NC
InChI
InChIKey=SPLVKBMIQSSFFN-UHFFFAOYSA-N
InChI=1S/C11H17N3O/c1-12-11(13-2)14-8-9-4-6-10(15-3)7-5-9/h4-7H,8H2,1-3H3,(H2,12,13,14)
Meobentine is an antiarrhythmic agent. Meobentine significantly increases the electrical ventricular fibrillation threshold in animal models. Meobentine may prevent induction of ventricular tachycardia or fibrillation, or reduce frequency of complex ventricular ectopy in selected patients refractory to other antiarrhythmic agents, but the response rate is relatively low.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Meobentine sulphate (bis[N-4-methoxybenzyl-N'N"-dimethylguanidine]sulphate): a new antidysrhythmic agent. | 1981 Sep |
|
| The antiarrhythmic activity of meobentine sulfate in man. | 1984 Jul-Aug |
|
| Antidysrhythmic actions of meobentine sulfate. | 1984 Jun |
|
| A comparison of the effects of bethanidine, meobentine and quinidine on the electrical activity of rat hearts in vivo and in vitro. | 1985 Mar |
|
| Meobentine sulfate: antiarrhythmic and electrophysiologic effects assessed by programmed electrical stimulation and ambulatory monitoring in patients with complex ventricular tachyarrhythmia. Report of a multicenter evaluation. | 1985 Oct |
|
| Studies on bethanidine and meobentine: direct and indirect effects of antifibrillatory drugs. | 1986 Nov-Dec |
Patents
Sample Use Guides
intravenous (16 mg/kg); oral (400 to 1000 mg every 6 hours, 3 days/dose interval).
Route of Administration:
Other
Glass microelectrodes were used to record transmembrane electrical activity from cells located just beneath the endocardial surface of segments of the right ventricular free wall of the rat heart during superfusion and electrical stimulation in vitro at 37 degrees C. Meobentine (4 to 20 microM) applied in vitro caused a prolongation of action potential duration and a delayed and slowed return of electrical excitability following an action potential.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
42765
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
C032896
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
46464-11-3
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
SUB08743MIG
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
C170161
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
T91E239Z1V
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
DTXSID30196849
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
m7181
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
3340
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
100000081475
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
4194
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110972
Created by
admin on Sat Dec 16 16:47:02 GMT 2023 , Edited by admin on Sat Dec 16 16:47:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
